TwinBeech Capital’s Revolution Medicines RVMD Stock Holding History

TwinBeech Capital’s Portfolio RVMD Stock Details RVMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-9,800	Closed	-$953K	–	642
2026 Q1	$953K	Buy	9,800 +7,100	+263%	+$717K	0.1%	257
2025 Q4	$215K	Buy	+2,700	New	+$177K	0.02%	528
2025 Q3	–	Sell	-33,750	Closed	-$1.24M	–	801
2025 Q2	$1.24M	Buy	+33,750	New	+$1.3M	0.03%	386
2024 Q3	–	Sell	-220,289	Closed	-$8.55M	–	858
2024 Q2	$8.55M	Buy	+220,289	New	+$8.23M	0.17%	154
2024 Q1	–	Sell	-7,486	Closed	-$215K	–	809
2023 Q4	$215K	Sell	7,486 -178,659	-96%	-$4.29M	﹤0.01%	601
2023 Q3	$5.15M	Buy	+186,145	New	+$5.52M	0.1%	259
2023 Q2	–	Sell	-162,148	Closed	-$3.51M	–	823
2023 Q1	$3.51M	Buy	+162,148	New	+$3.99M	0.07%	295
2021 Q3	–	Sell	-20,701	Closed	-$657K	–	731
2021 Q2	$657K	Buy	+20,701	New	+$723K	0.08%	269

Other funds holding RVMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

TwinBeech Capital's RVMD Position: Q2 2026 in Review

TwinBeech Capital sold out of Revolution Medicines (RVMD) in Q2 2026, closing a stake of 9,800 shares — an estimated $953K sold.

TwinBeech Capital first reported a position in RVMD in Q2 2021 and held it in 8 quarters. The position peaked at $8.55M in Q2 2024. 696 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

TwinBeech Capital reported no remaining Revolution Medicines position as of Q2 2026 after selling out during the quarter.
TwinBeech Capital sold 9,800 Revolution Medicines shares in Q2 2026, an estimated $953K.
TwinBeech Capital first reported a position in Revolution Medicines in Q2 2021 and held it in 8 quarters.
TwinBeech Capital's Revolution Medicines position peaked at $8.55M in Q2 2024.
696 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on TwinBeech Capital's 13F filing for Q2 2026, filed 14 Aug 2026.